Cediranib
Recurrent Cervical Cancer
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Cervical Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Advenchen Laboratories, LLC | Phase 3 | BB |
Recombinant Interleukin-12 National Cancer Institute (NCI) | Phase 1 | CC |
Temsirolimus University of Southern California | Phase 1 | CC |
Irinotecan National Cancer Institute (NCI) | Phase 1 | CC |
Triapine National Cancer Institute (NCI) | Phase 1 | CC |
Abi-007 National Cancer Institute (NCI) | Phase 1 | CC |
7-hydroxystaurosporine National Cancer Institute (NCI) | Phase 1 | CC |
Vinorelbine University of Southern California | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →